PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.
No takes yet. Share an insight, caveat, or question.
Aguiar et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: